Business
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
The scientific poster highlights the role of pro-inflammatory macrophages and monocytes in reducing regulatory T cell (Treg) immunomodulatory suppressive
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nThe scientific poster highlights the role of pro-inflammatory macrophages and monocytes in reducing regulatory T cell (Treg) immunomodulatory suppressive function and the anti-inflammatory effect of Treg-enhancing therapies combined with drugs that suppress M1 pro-inflammatory activated monocytes and macrophages in ALS;\n\n\n\nCOYA 302 is a dual-mechanism investigational biologic combination comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being investigated for the treatment of ALS.\n\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, today announced the acceptance and presentation of a poster at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting on October 4th, 2023.\n\n\nThe experimental data generated in samples from ALS patients highlight the role of M1 pro-inflammatory monocytes and macrophages in reducing the immunomodulatory anti-inflammatory function of Tregs. Also documented is the significant effect of combination therapies that both enhance Treg function and suppress M1 activated macrophages and monocytes resulting in the reduction of pro-inflammatory cytokines known to be involved in inflammatory response and tissue damage. Results of this study reinforce the potential of COYA 302 that may address the complex pathophysiology and multiple pathways involved in the progression and severity of ALS.\n\n\nFred Grossman, President and Chief Medical Officer said, “The data being presented provides additional mechanistic rationale and support for combination therapies targeting multiple immune pathways in ALS.”\n\n\nDetails of the poster presentation at the NEALS Annual Meeting are as follows:\n\n\nDate: October 5th, 2023\nTitle: Monocytes/Macrophages Impair Regulatory T-Lymphocyte Suppressive Function\nPoster Number: 132\n\n\nFor Conference Information visit: https://neals.org/als-researchers/annual-neals-meeting\n\n\nAbout Coya Therapeutics, Inc.\n\n\nHeadquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation ...